Insider Selling: Medpace (NASDAQ:MEDP) Director Sells 3,858 Shares

Medpace Holdings, Inc. (NASDAQ:MEDP – Get Free Report) Director Robert Kraft sold 3,858 shares of the stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $617.81, for a total value of $2,383,510.98. Following the completion of the transaction, the director directly owned 955 shares in the company, valued at $590,008.55. This represents a 80.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Medpace Stock Down 1.8%

Shares of NASDAQ:MEDP traded down $10.92 during trading on Friday, hitting $600.65. The stock had a trading volume of 186,741 shares, compared to its average volume of 343,212. Medpace Holdings, Inc. has a 12-month low of $373.00 and a 12-month high of $677.90. The stock has a market capitalization of $16.76 billion, a price-to-earnings ratio of 35.21, a price-to-earnings-growth ratio of 2.76 and a beta of 1.15. The stock has a 50-day simple moving average of $562.52 and a two-hundred day simple moving average of $493.80.

Get Medpace alerts:

Medpace (NASDAQ:MEDP – Get Free Report) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. During the same quarter in the prior year, the firm earned $3.10 earnings per share. Medpace’s revenue for the quarter was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, sell-side analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Institutional Investors Weigh In On Medpace

Several hedge funds have recently bought and sold shares of the stock. Corient Private Wealth LP increased its holdings in shares of Medpace by 291.4% during the 2nd quarter. Corient Private Wealth LP now owns 6,314 shares of the company’s stock valued at $3,344,000 after purchasing an additional 4,701 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Medpace during the second quarter worth $5,460,000. California State Teachers Retirement System grew its position in Medpace by 53,619.6% during the second quarter. California State Teachers Retirement System now owns 13,989,649 shares of the company’s stock valued at $7,408,778,000 after buying an additional 13,963,607 shares during the period. HB Wealth Management LLC grew its position in Medpace by 3.9% during the second quarter. HB Wealth Management LLC now owns 1,858 shares of the company’s stock valued at $984,000 after buying an additional 69 shares during the period. Finally, AlphaGrep UK Ltd purchased a new position in Medpace in the second quarter valued at $466,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on the stock. TD Cowen upped their price objective on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a report on Friday, July 24th. Barclays set a $600.00 target price on shares of Medpace in a report on Thursday, July 23rd. BMO Capital Markets boosted their target price on shares of Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research report on Friday, July 24th. Jefferies Financial Group lowered shares of Medpace from a “buy” rating to a “hold” rating and upped their price target for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $535.00 price target on shares of Medpace in a research report on Thursday, July 23rd. Three equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat.com, Medpace has an average rating of “Hold” and a consensus price target of $584.18.

View Our Latest Stock Analysis on Medpace

About Medpace

(Get Free Report)

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

Featured Articles

• Five stocks we like better than Medpace
• 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
• IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
• Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
• Okta Stock Surges 29%—Is $200 the Next Stop?

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.